Sign in
4

Changes in Ownership

Enliven Therapeutics, Inc. Filed Acc 0001415889-24-006358

CHIEF SCIENTIFIC OFFICER sold 12,000 shares at an average $16.42 ($197,006)

  • CHIEF SCIENTIFIC OFFICER acquired 12,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER 2024-02-29 Option exercise 10b5-1 +12,000 $1.12 $13,440 12,000 D: show line 1 in the form
Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER 2024-02-29 Sale 10b5-1 −10,195 $16.30 $166,152 1,805 D: show line 2 in the form
Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER 2024-02-29 Sale 10b5-1 −1,805 $17.09 $30,854 0 D: show line 3 in the form
Open-market sales · 12,000 sh · avg $16.42 · $197,006

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER 2024-02-29 Option exercise · Stock Option (right to buy) 10b5-1 −12,000 272,550 D: show line 4 in the form
Loading xslF345X05/form4-03042024_100311.xml…